January 29-31 2019
Boston, MA

 

 

Day One
Wednesday January 30th, 2019

Day Two
Thursday January 31st, 2019

09.00
Coffee & Registration

09.45
Chair Opening Remarks

DNA Damage Response Inhibitor Combinations

10.00
Leveraging DNA Repair Inhibitor Combinations to Overcome PARP Inhibitor Resistance

10.30
PARP and PD-1/L1: The Perfect Partners?

  • Ross Stewart Director, Early Development & Translational Oncology, Pfizer

11.00
Morning Refreshments & Networking

11.30
Preclinical Anti-tumor Activity of Niraparib and its Combination with Anti-PD-1 Therapy

  • Jing Yu Wang Senior Director, Translational Strategy and Research , Tesaro

12.00
PARP Inhibitor Combinations Targeting Glioblastoma Stem-like Cells

  • Jianfang Ning Assistant Professor, Neurosurgery , University of Minnesota Medical School

12.30
Panel Discussion: Developing Optimal Combination Strategies in the Clinic

13.30
Lunch & Networking

Advances in Clinical Biomarker Development

14.30
2X 121 (E7449), a Dual PARP1/2 and Tankyrase1/2 Inhibitor & Its Novel Drug Response Predictor Biomarker

15.00
Generation of DDR pathways-centered ctDNA panel to inform patient stratification for immunotherapy

15.30
Chair’s Closing Remarks

15.45
Close of Summit